Journal of the Practice of Cardiovascular Sciences (Jan 2017)
HeartWare HVAD: Postoperative issues in our first patient
Abstract
Ventricular assist devices (VADs) serve as a bridge to heart transplant or destination therapy in end stage heart failure. HeartWare HVAD is a second generation, non pulsatile, magnetically levitated centrifugal pump, which is preload dependent and afterload sensitive. It has an inlet that is cored into the left ventricular wall and an outflow that is attached to a graft which is sutured into the ascending aorta. The Registry to Evaluate the HeartWare Left Ventricular Assist System (ReVOLVE) registry has reported a 2 year survival of 76% and 5 year survival of 59%. We present our experience of the first HeartWare 2 HVAD implanted at our institute.
Keywords